Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study

Journal of the National Cancer Institute

Volumn 93, Issue 1, 2001, Pages 22-30

  Kluin Nelemans, Hanneke C ^a,h   Zagonel, Vittorina ^b   Anastasopoulou, Anastasia ^c   Bron, Dominique ^d   Roozendaal, Klaas J ^e   Noordijk, Ed M ^a   Musson, Helen ^c   Teodorovic, Ivana ^c   Maes, Brigitte ^f   Carbone, Antonino ^b   Carde, Patrice ^g   Thomas, José ^f  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c EORTC DATA CENTER   (Belgium)

^d JULES BORDET INSTITUTE   (Belgium)

^e ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ADOLESCENT; ADULT; ALOPECIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; INFECTION; LUNG COMPLICATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; STANDARD; STOMACH PERFORATION; THROMBOCYTOPENIA;

EID: 0035798799     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.1.22     Document Type: Article

References (42)

1. Treatment of non-Hodgkin's lymphoma
2. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma
3. Updated clinical experience with MACOP-B
4. Unfavorable histologies of non-Hodgkin's lymphoma treated with Pro-MACE-CytaBOM: A groupwide Southwest oncology group study
5. m-BACOD treatment for intermediate- and high-grade malignant lymphomas: A Southwest oncology group phase II trial
6. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
7. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project
8. Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): The 1980-1985 EORTC trial
9. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma
10. EORTC study of non-Hodgkin's lymphoma: Phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma
11. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation
12. Intensive cytotoxic therapy followed by autologous bone marrow transplantation for non-Hodgkin's lymphoma of high-grade malignancy
13. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma
14. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy
15. European experience of ABMT in non-Hodgkin's lymphoma and Hodgkin's disease
16. Bone marrow transplantation in the treatment of patients with lymphoma
17. A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group
18. Parma international protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation
19. Comparison of survival curves
20. Regression models and life-table
21. Evaluation of survival data and two new rank order statistics arising in its consideration
22. Interim analysis: The alpha spending function approach
23. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
24. Interim analyses and stopping rules in cancer clinical trials
25. A predictive model for aggressive non-Hodgkin's lymphoma
26. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients
27. Comparison of standard CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma
28. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
29. Failure of first-line inductive high-dose chemotherapy (HDC) in poor-risk patients (PTS) with aggressive lymphoma: Updated results of the randomized LNH93-3 study
30. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's Lymphoma cooperative study group
31. High dose chemotherapy with autologous stem cell transplantation in aggressive NHL: Analysis of a randomized multi-center study
32. Frontline high dose chemotherapy with autologous stem cell transplantation is not superior to CHOP regimen for adult patients with non IPI high risk intermediate or high grade NHL: Results of a randomized trial by the GOELAMS
33. Early autologous stem cell transplantation as first-line therapy in poor prognosis non Hodgkin's lymphoma (NHL): An Italian randomized trial
34. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2
35. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: Randomized Italian multicenter study
36. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies
37. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma
38. Myelodysplastic syndrome after autologous transplantation for lymphoma: The price of progress
39. Solid cancers after bone marrow transplantation
40. Malignancies after hematopoietic stem cell transplantation: Many questions, some answers
41. Report of the Committee on Hodgkin's Disease Staging Classification